A Trial to Evaluate the Safety and Immunogenicity of Monovalent H5N1 Vaccine in Adults ≥18 Yrs of Age

Trial Profile

A Trial to Evaluate the Safety and Immunogenicity of Monovalent H5N1 Vaccine in Adults ≥18 Yrs of Age

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A; AS03B
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 21 Oct 2011 Secondary endpoint 'Seroconversion-rate' has been met (3063141).
    • 21 Oct 2011 Primary endpoint 'Geometric-mean-antibody-titre' has been met (3063141).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top